Featuring an interview with Prof Karim Fizazi, including the following topics:

• Perspectives on the PROTEUS Phase III trial evaluating the addition of apalutamide to standard therapy for high-risk localized prostate cancer (0:00)
• Mechanism of action of opevesostat and potential role in castration-resistant prostate cancer with androgen receptor mutations (15:37)
• Perspectives on alpha- and beta-emitting radiopharmaceuticals in the treatment of prostate cancer (22:47)
• Novel antibody-drug conjugates and proteolysis-targeting chimeras (30:43)
• Treatment approaches for metastatic hormone-sensitive prostate cancer — de novo symptomatic presentation versus PSMA-only metastatic recurrence after local therapy (34:51)
• Role of intermittent therapy in the treatment of prostate cancer (38:48)
• Treatment intensification approaches in prostate cancer (41:38)
• Case: A man in his late 60s with de novo PSMA PET-positive metastatic castration-sensitive prostate cancer (45:25)

CME information and select publications

Featuring perspectives from Prof Susana Banerjee, including the following topics:

• Case: A woman in her mid 50s with multiregimen-recurrent low-grade serous ovarian cancer and a KRAS G12V mutation who receives avutometinib/defactinib with response, asymptomatic creatine phosphokinase elevation and mild facial rash — Dr Stover (0:00)
• Case: A woman in her early 30s with recurrent metastatic low-grade serous ovarian cancer, originally offered hospice due to poor condition, who receives avutometinib/defactinib with an excellent response — Dr Hussein (7:58)
• Case: A woman in her late 30s with multiregimen-recurrent folate receptor alpha-positive low-grade serous ovarian cancer (HER2 IHC 2+) who receives mirvetuximab soravtansine — Dr Cobb (18:21)

CME information and select publications

Featuring perspectives from Prof Susana Banerjee, including the following topics:

• Overview of the biology and treatment of low-grade serous ovarian cancer (0:00)
• Mechanism of action of avutometinib/defactinib (10:16)
• RAMP 201 Trial: Avutometinib/defactinib in recurrent low-grade serous ovarian cancer (14:32)
• Ongoing clinical trials in low-grade serous ovarian cancer (27:57)

CME information and select publications